National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 59742-59743 [2021-23508]
Download as PDF
<![CDATA[
jspears on DSK121TN23PROD with NOTICES1
59742
Federal Register / Vol. 86, No. 206 / Thursday, October 28, 2021 / Notices
Patient Protection and Affordable Care
Act, Public Law 111–148, which added
section 2713 to the Public Health
Service Act, 42 U.S.C. 300gg–13, HRSA
established the Guidelines in 2011
based on a study and recommendations
by the Institute of Medicine, now
known as the National Academy of
Medicine, developed under a contract
with the Department of Health and
Human Services. Since then, there have
been advancements in science and gaps
identified in these guidelines, including
a greater emphasis on practice-based
clinical considerations. In March 2016,
HRSA awarded a 5-year cooperative
agreement to the ACOG to convene a
coalition representing clinicians,
academics, and consumer-focused
health professional organizations to
conduct a rigorous review of current
scientific evidence and make
recommendations to HRSA regarding
updates to the existing Guidelines.
HRSA awarded ACOG the cooperative
agreement to improve adult women’s
health across the lifespan by engaging a
coalition of health professional
organizations to review evidence and
recommend updates to the HRSAsupported Guidelines. HRSA would
then decide whether to support, in
whole or in part, the recommended
updates to the Guidelines. Under the
cooperative agreement, ACOG formed
WPSI, consisting of an Advisory Panel
and two expert committees, the
Multidisciplinary Steering Committee
(MSC) and the Dissemination and
Implementation Steering Committee
(DISC), which are comprised of a broad
coalition of organizational
representatives who are experts in
disease prevention and women’s health
issues. Through oversight by the
Advisory Panel, MSC and DISC support
the development and implementation of
the Guidelines through the review of
existing evidence and recommendation
development. Specifically, the MSC
examines the evidence to develop new
and update existing recommendations
for women’s preventive services. DISC
takes the HRSA-approved
recommendations, developed by the
MSC, and works to disseminate the
recommendations through the
development of implementation tools
and resources for both patients and
practitioners to support the adoption
and utilization of the recommendations.
In March 2021, HRSA awarded a
subsequent cooperative agreement to
ACOG to further review and recommend
updates to the Guidelines. Under this
cooperative agreement, beginning on
March 1, 2021, ACOG engaged in a
process to consider and review new
VerDate Sep<11>2014
17:34 Oct 27, 2021
Jkt 256001
information. Following
recommendations by ACOG, HRSA will
decide whether to support, in whole or
in part, its recommended updates to the
guidelines.
Under the cooperative agreement,
ACOG will base its recommended
updates to the Guidelines on review and
synthesis of existing clinical guidelines
and new scientific evidence, following
the National Academy of Medicine
standards for establishing foundations
for and rating strengths of
recommendations, articulation of
recommendations, as well as external
reviews. Additionally, ACOG will
incorporate processes to assure
opportunity for public comment,
including participation by patients and
consumers, in the development of the
updated Guideline recommendations.
This notice solicits comments from
the public on draft recommendations for
providing contraception and screening
for HIV infection. The updated draft
recommendations are provided below.
WPSI will consider and, as necessary,
incorporate public comment. HRSA will
then decide whether to support, in
whole or in part, the recommended
updates to the guidelines.
Contraception
ACOG, through the WPSI/MSC, made
updates to the clinical recommendation
statement to clarify the terminology
from contraceptive methods to
contraceptives. The Committee has also
removed the term ‘‘female-controlled
contraceptives’’ to allow women to
purchase male condoms for pregnancy
prevention. Lastly, the Committee has
further defined the existing components
of contraceptive follow-up care to
include the management and evaluation
of and changes to—including the
removal, continuation, and
discontinuation of—the contraceptive.
‘‘The Women’s Preventive Services
Initiative recommends adolescent and adult
women have access to the full range of
contraceptives and contraceptive care to
prevent unintended pregnancies and improve
health outcomes. Contraceptive care includes
screening, counseling, education, and
provision of contraceptives (including in the
immediate postpartum period). Contraceptive
care also includes follow-up care (e.g.,
management and evaluation of and changes
to, including, removal, continuation,
discontinuation of, the contraceptive
method).
The Women’s Preventive Services
Initiative recommends the full range of U.S.
Food and Drug Administration (FDA)
approved contraceptives, effective family
planning practices, and sterilization
procedures be available as part of
contraceptive care.
The full range of contraceptive methods
currently identified by FDA include: (1)
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Sterilization surgery for women, (2)
implantable rods, (3) copper intrauterine
devices, (4) intrauterine devices with
progestin (all durations and doses), (5)
injectable contraceptives, (6) oral
contraceptives (combined pill), (7) oral
contraceptives (progestin only), (8) oral
contraceptives (extended or continuous use),
(9) the contraceptive patch, (10) vaginal
contraceptive rings, (11) diaphragms, (12)
contraceptive sponges, (13) cervical caps,
(14) condoms, (15) spermicides, (16)
emergency contraception (levonorgestrel);
and (17) emergency contraception (ulipristal
acetate); additional methods as identified by
the FDA.’’
Screening for HIV Infection
ACOG, through the WPSI/MSC, has
recommended minor updates to the
screening for HIV infection
recommendation statement to specify
that screening should begin at age 15
and older, and that earlier detection
should be based on a review of patient
risk factors.
‘‘The Women’s Preventive Services
Initiative recommends all women, ages 15
and older, receive a screening test for HIV at
least once during their lifetime. Earlier or
additional screening should be based on risk,
and re-screening annually or more often may
be appropriate beginning at age 13 for
adolescents and women with an increased
risk of HIV infection.
The Women’s Preventive Services
Initiative recommends risk assessment and
prevention education for human
immunodeficiency virus (HIV) infection
beginning at age 13 and continuing at least
annually throughout the lifespan as
determined by risk. A screening test for HIV
is recommended for all pregnant women
upon initiation of prenatal care with
rescreening during pregnancy based on risk
factors. Rapid HIV testing is recommended
for pregnant women who present in labor
with an undocumented HIV status.’’
Members of the public can view each
complete updated draft
recommendation statement by accessing
the initiative’s web page at https://
www.womenspreventivehealth.org/.
Diana Espinosa,
Acting Administrator.
[FR Doc. 2021–23498 Filed 10–27–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
E:\FR\FM\28OCN1.SGM
28OCN1
Federal Register / Vol. 86, No. 206 / Thursday, October 28, 2021 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Research Education
Program Advancing the Careers of a Diverse
Research Workforce (R25 Clinical Trial Not
Allowed).
Date: November 19, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: James T. Snyder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892–9834, (240) 669–5060,
james.snyder@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 25, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–23508 Filed 10–27–21; 8:45 am]
BILLING CODE 4140–01–P
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Retinopathies and Other Eye
Diseases.
Date: November 19, 2021.
Time: 10:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alessandra C. Rovescalli,
Ph.D., Scientific Review Officer, National
Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm. 5205
MSC7846, Bethesda, MD 20892, (301) 435–
1021, rovescaa@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Special
Topics in Aging: Diet, Immune Response,
Juvenile Protective Factors, Cognition,
Dementia, and Outcomes on Aging.
Date: November 29, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Samuel C. Edwards, Ph.D.,
Chief, BDCN IRG, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 5210, MSC 7846,
Bethesda, MD 20892, (301) 435–1246,
edwardss@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 25, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–23509 Filed 10–27–21; 8:45 am]
BILLING CODE 4140–01–P
jspears on DSK121TN23PROD with NOTICES1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HOMELAND
SECURITY
Center for Scientific Review; Notice of
Closed Meetings
Coast Guard
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
17:34 Oct 27, 2021
Jkt 256001
[Docket No. USCG–2021–0742]
National Merchant Marine Personnel
Advisory Committee Meeting
U.S. Coast Guard, Department
of Homeland Security.
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The National Merchant
Marine Personnel Advisory Committee
(Committee) and its Working Groups
will meet in Piney Point, MD, to discuss
issues relating to personnel in the
United States Merchant Marine
including the training, qualifications,
SUMMARY:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
59743
certification, documentation, and fitness
of mariners.
DATES:
Meetings: The National Merchant
Marine Personnel Advisory Committee
and its Working Groups are scheduled
to meet on Tuesday, November 16,
2021, from 8:30 a.m. until 4:30 p.m.,
Wednesday, November 17, 2021, from
8:30 a.m. until 4:30 p.m., and the full
Committee is scheduled to meet on
Thursday, November 18, 2021, from
9:00 a.m. until 4:30 p.m. These meetings
may adjourn early if the Committee has
completed its business.
Comments and supporting
documentation: To ensure your
comments are received by Committee
members before the meetings, submit
your written comments no later than
November 4, 2021.
ADDRESSES: The meeting will be held at
the Harry Lundeberg School of
Seamanship at 45353 Saint Georges
Avenue Piney Point, MD 20674;
additional information can be found at:
https://www.seafarers.org/training-andcareers/jobs/the-seafarers-harrylundeberg-school-of-seamanship/.
Pre-registration Information: Preregistration is required for in-person
access to the meeting, but is not
required for anyone attending via
teleconference. In-person attendance to
the meeting will be limited to the first
49 registrants, with priority for members
of the Committee and Coast Guard
support staff. If you are not a member
of the Committee and do not represent
the Coast Guard, you must request inperson attendance by contacting the
individual listed in the FOR FURTHER
INFORMATION CONTACT section of this
notice. You will receive a response
noting if you are able to attend inperson or if the in-person attendance
roster is full. Additionally, the N–
MERPAC mailing list will receive a
notification when the in-person
attendance roster is full.
Attendees at the meeting will be
required to follow COVID–19 safety
guidelines promulgated by the Centers
for Disease Control and Prevention
(CDC), which may include the need to
wear masks and by completing
Certification of Vaccination Form OMB
Control No. 3206–0277, or providing
proof of vaccination. This form can be
accessed at:
CertificationVaccinationPRAv7.pdf
(menlosecurity.com). You may be asked
to show this form when entering the
facility. Please maintain this form
during your visit. Masks will be
provided for attendees. CDC guidance
on COVID protocols can be found here:
E:\FR\FM\28OCN1.SGM
28OCN1
]]>Agencies
[Federal Register Volume 86, Number 206 (Thursday, October 28, 2021)]
[Notices]
[Pages 59742-59743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23508]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
[[Page 59743]]
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Research Education Program
Advancing the Careers of a Diverse Research Workforce (R25 Clinical
Trial Not Allowed).
Date: November 19, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: James T. Snyder, Ph.D., Scientific Review
Officer, Scientific Review Program, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, 5601 Fishers
Lane, Room 3G31, Rockville, MD 20892-9834, (240) 669-5060,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 25, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-23508 Filed 10-27-21; 8:45 am]
BILLING CODE 4140-01-P
